X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs CIPLA - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD CIPLA LUPIN LTD/
CIPLA
 
P/E (TTM) x 30.0 32.8 91.3% View Chart
P/BV x 2.9 2.9 100.3% View Chart
Dividend Yield % 0.6 0.6 97.7%  

Financials

 LUPIN LTD   CIPLA
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
CIPLA
Mar-18
LUPIN LTD/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,465663 221.0%   
Low Rs727479 151.8%   
Sales per share (Unadj.) Rs349.6189.0 184.9%  
Earnings per share (Unadj.) Rs5.617.6 31.6%  
Cash flow per share (Unadj.) Rs29.634.0 86.9%  
Dividends per share (Unadj.) Rs5.003.00 166.7%  
Dividend yield (eoy) %0.50.5 86.8%  
Book value per share (Unadj.) Rs300.3176.7 169.9%  
Shares outstanding (eoy) m452.08805.12 56.2%   
Bonus/Rights/Conversions ESOPSESOP-  
Price / Sales ratio x3.13.0 103.8%   
Avg P/E ratio x197.232.5 607.7%  
P/CF ratio (eoy) x37.116.8 220.8%  
Price / Book Value ratio x3.63.2 113.0%  
Dividend payout %90.017.1 527.6%   
Avg Mkt Cap Rs m495,502459,724 107.8%   
No. of employees `00017.023.6 72.2%   
Total wages/salary Rs m28,64726,901 106.5%   
Avg. sales/employee Rs Th9,273.66,446.1 143.9%   
Avg. wages/employee Rs Th1,681.01,139.4 147.5%   
Avg. net profit/employee Rs Th147.4600.0 24.6%   
INCOME DATA
Net Sales Rs m158,042152,193 103.8%  
Other income Rs m1,5043,577 42.0%   
Total revenues Rs m159,545155,769 102.4%   
Gross profit Rs m31,47528,264 111.4%  
Depreciation Rs m10,85913,228 82.1%   
Interest Rs m2,0441,142 178.9%   
Profit before tax Rs m20,07617,470 114.9%   
Minority Interest Rs m-710-   
Prior Period Items Rs m35-28 -126.6%   
Extraordinary Inc (Exp) Rs m-14,644-775 1,889.0%   
Tax Rs m2,8852,501 115.3%   
Profit after tax Rs m2,51314,166 17.7%  
Gross profit margin %19.918.6 107.2%  
Effective tax rate %14.414.3 100.4%   
Net profit margin %1.69.3 17.1%  
BALANCE SHEET DATA
Current assets Rs m122,095108,141 112.9%   
Current liabilities Rs m50,95638,322 133.0%   
Net working cap to sales %45.045.9 98.1%  
Current ratio x2.42.8 84.9%  
Inventory Days Days8597 87.2%  
Debtors Days Days12074 161.2%  
Net fixed assets Rs m129,876109,411 118.7%   
Share capital Rs m9041,610 56.2%   
"Free" reserves Rs m134,866140,682 95.9%   
Net worth Rs m135,771142,292 95.4%   
Long term debt Rs m64,24536,621 175.4%   
Total assets Rs m263,054228,606 115.1%  
Interest coverage x10.816.3 66.4%   
Debt to equity ratio x0.50.3 183.9%  
Sales to assets ratio x0.60.7 90.2%   
Return on assets %1.76.7 25.9%  
Return on equity %1.910.0 18.6%  
Return on capital %3.710.0 37.4%  
Exports to sales %032.8 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA49,883 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53,14151,691 102.8%   
Fx outflow Rs m19,33521,033 91.9%   
Net fx Rs m33,80730,658 110.3%   
CASH FLOW
From Operations Rs m17,51214,628 119.7%  
From Investments Rs m-14,073-8,540 164.8%  
From Financial Activity Rs m-14,921-3,855 387.1%  
Net Cashflow Rs m-11,4822,431 -472.3%  

Share Holding

Indian Promoters % 46.6 16.0 291.3%  
Foreign collaborators % 0.2 20.8 1.0%  
Indian inst/Mut Fund % 11.3 12.2 92.6%  
FIIs % 31.9 23.7 134.6%  
ADR/GDR % 0.0 1.1 -  
Free float % 10.1 26.2 38.5%  
Shareholders   98,259 161,166 61.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   PLETHICO PHARMA  BIOCON LTD  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare LUPIN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; ITC & Reliance Top Gainers(12:30 pm)

Share markets in India are presently trading marginally higher. Sectoral indices are trading mixed with stocks in the energy sector and realty sector witnessing maximum buying interest.

Related Views on News

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)

Jan 11, 2019

The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling

This Trend Will Produce a Once in a Lifetime Opportunity to Buy Stocks(The 5 Minute Wrapup)

Jan 15, 2019

Unlike his habit of pouring out stock wisdom in his annual letters to shareholders, Buffett spoke of this trend only once every few decades.

This Created Multibagger Stocks in the US and Japan and Now It's Happening in India(The 5 Minute Wrapup)

Jan 17, 2019

It may not just create tremendous stock market wealth, but also push several Indian companies in the reckoning of global leaders.

My Next Small Cap Recommendation Is Practically a 'No Brainer'(Profit Hunter)

Jan 14, 2019

With a strong debt free balance sheet in its favour, attractive dividends and trading at almost lifetime lows, this investing idea is almost a no brainer.

Sensex 100,000 Will Happen and I Want You to Profit from It(Profit Hunter)

Jan 18, 2019

These indicators reveal that the interest in stock market investing is only growing and set to grow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Jan 24, 2019 01:35 PM

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD 8-QTR ANALYSIS

COMPARE LUPIN LTD WITH

MARKET STATS